BridgeBio’s Infigratinib Signals Breakthrough in Pediatric Achondroplasia Trial

BridgeBio Pharma announced yesterday the successful completion of the pivotal Phase 3 PROPEL 3 study evaluating Infigratinib. The data demonstrate meaningful clinical benefits in children with achondroplasia, the most common form of dwarfism. With the primary endpoint reached, a potential regulatory filing for the oral therapy moves closer to market approval.

• Strong growth: Annual growth velocity increased by 1.74 cm compared with the placebo group.
• Milestone: First statistically significant improvement in body proportionality observed.
• Safety: Well tolerated with no serious treatment-related adverse events.
• Timeline: Submissions to FDA and EMA for regulatory approval are planned for the second half of 2026.

Compelling study data

In the global Phase-3 trial, 113 children aged 3 to 18 participated. The primary endpoint—the change in annual height velocity (AHV) from baseline after 52 weeks—was met with high statistical significance (p<0.0001). Treated patients exhibited a mean growth differential of +1.74 cm per year versus controls. Could the oral therapy redefine the current standard of care for dwarfism? The results suggest Infigratinib offers competitive efficacy relative to the currently available injectable treatments.

Improvement in body proportionality

A key aspect of PROPEL-3 is body proportionality, a secondary endpoint that has been difficult to influence with existing therapies. BridgeBio reported the first statistically significant improvement in this metric for achondroplasia treatment. Notably, among children under eight, a pronounced reduction in the ratio of upper to lower body segments was observed. Medical experts regard this as a meaningful advancement, since better proportionality can enhance physical endurance and independence in daily activities.

Should investors sell immediately? Or is it worth buying BridgeBio Pharma?

Safety profile and outlook

Over a one-year treatment period, Infigratinib demonstrated a favorable safety profile. There were no serious adverse events linked to the drug, and no study discontinuations or dose reductions due to tolerability issues. Three participants (about 4%) showed elevated phosphate levels, but these were mild and asymptomatic.

Based on these findings, BridgeBio is moving forward with global regulatory preparations. The company plans to submit the NDA to the U.S. FDA and the MAA to the European Medicines Agency (EMA) in the second half of 2026. Given its Breakthrough Therapy status, a focused and accelerated review process is anticipated. In parallel, BridgeBio is already planning a Phase-3 study for hypochondroplasia to broaden the drug’s application to related genetic conditions.